Teva’s Complex Generic Ambitions Number Nearly A Dozen In 2021
As Israeli Firm Publishes Full-Year Results
Israeli giant Teva is hoping to follow the recent big-ticket launches of generic Truvada/Atripla and NuvaRing with multiple complex generics launches in the US this year. Management discussed individual product opportunities as Teva disclosed full-year financial earnings.
You may also be interested in...
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Perrigo has moved to allay more serious concerns around its generic ProAir inhaler device, but concedes that it is highly unlikely the lucrative respiratory product will return to the market this year.
Amgen has announced the launch of its biosimilar version of Rituxan (rituximab), Riabni, in the US market, further expanding the firm’s oncology biosimilars portfolio.